Test Catalog

Test Id : CSMEU

Controlled Substance Monitoring Enhanced Profile with Reflex, 21 Drug Classes, High Resolution Mass Spectrometry and Immunoassay Screen, Random, Urine

Useful For
Suggests clinical disorders or settings where the test may be helpful

Detecting drug use involving stimulants, barbiturate, benzodiazepines, cocaine, opioids, tetrahydrocannabinol, and alcohol

 

This test is not intended for use in employment-related testing.

Profile Information
A profile is a group of laboratory tests that are ordered and performed together under a single Mayo Test ID. Profile information lists the test performed, inclusive of the test fee, when a profile is ordered and includes reporting names and individual availability.

Test Id Reporting Name Available Separately Always Performed
LPCM List Patient's Current Medications No Yes
ADULT Adulterants Survey, U Yes Yes
PNRCH Drug Immunoassay Panel, U No Yes
TOPSU Targeted Opioid Screen, U Yes, Bill Only Yes
TABSU Targeted Benzodiazepine Screen, U Yes, Bill Only Yes
TSTIM Targeted Stimulant Screen, U Yes, Bill Only Yes
ETGSR Ethyl Glucuronide Scrn w/Reflex, U No Yes

Reflex Tests
Lists tests that may or may not be performed, at an additional charge, depending on the result and interpretation of the initial tests.

Test Id Reporting Name Available Separately Always Performed
COKEU Cocaine and metabolite Conf, U Yes No
BARBU Barbiturates Confirmation, U Yes No
THCU Carboxy-THC Confirmation, U Yes No
ETGC Ethyl Glucuronide Confirmation, U Yes No

Testing Algorithm
Delineates situations when tests are added to the initial order. This includes reflex and additional tests.

Testing begins with an adulterant survey. If the sample is found to be adulterated, testing will end, and the remaining tests will be canceled.

 

If the specimen is normal or only diluted, remaining testing will continue.

 

If immunoassay screen is positive, confirmation testing can be ordered separately. Confirmation with quantification of positives for barbiturates, cocaine and metabolites, tetrahydrocannabinol metabolite, and ethyl glucuronide/ethyl sulfate will be performed at an additional charge.

Method Name
A short description of the method used to perform the test

ADULT: Spectrophotometry (SP)

PNRCH: Screened by Immunoassay/Confirmed by Gas Chromatography-Mass Spectrometry (GC-MS)

TOPSU, TABSU, TSTIM: Liquid Chromatography-Tandem Mass Spectrometry, High-Resolution Accurate Mass (LC-MS/MS HRAM)

ETGSR: Screened by Immunoassay/Confirmed by Liquid Chromatography-Tandem Mass Spectrometry

NY State Available
Indicates the status of NY State approval and if the test is orderable for NY State clients.

Yes

Reporting Name
Lists a shorter or abbreviated version of the Published Name for a test

CSM Enhanced Profile,21, HRMS/IA, U

Aliases
Lists additional common names for a test, as an aid in searching

"J" (Jane) Tetrahydrocannabinol

6-monoacetylmorphine (heroin metabolite)

7-Amino Flunitrazepam (Metabolite of Flunitrazepam (Rohypnol)

7-Aminoclonazepam

Adderall (Amphetamine)

ADHD

Adipex-P (Phentermine)

Adzenys ER (Amphetamine)

Alcohol biomarkers

Alprazolam (Xanax)

Amobarbital (Amytal)

Amphetamines

Amytal (Amobarbital)

Angel Dust (Phencyclidine)

Ativan (Lorazepam)

Barbital (Phenobarbital)

Barbiturates

Benzodiazepines

Benzoylecgonine (Cocaine Metabolite)

Buprenorphine (Buprenex, Suboxone)

Butabarbital (Butisol)

Butalbital (Fiorinal)

Butisol (Butabarbital)

Cannabinoids (Tetrahydrocannabinol)

Chlordiazepoxide (Librium)

Clonazepam

Clorazepate (Tranxene)

Cocaine

Codeine

Codeine (Tylenol #3)

Codeine-6-beta-glucuronide (codeine metabolite)

Coke (Cocaine)

Compliance monitoring

Concerta (Methylphenidate)

Crack (Cocaine)

Dalmane (Flurazepam)

Date Rape Drug (Rohypnol [Flunitrazepam])

Desalkyl Flurazepam (Metabolite)

Desoxyn (Methamphetamine)

Dexedrine (Amphetamine)

Diazepam (Valium)

Dihydrocodeine(hydrocodone metabolite)

Drug Screen

Drugs of Abuse

Dyanavel XR (Amphetamine)

Ecstasy

EDDP (Methadone metabolite)

Fentanyl (Actiq, Duragesic, Fentora)

Fiorinal (Butalbital)

Flunitrazepam (Rohypnol)

Flurazepam (Dalmane)

Halcion (Triazolam)

Heroin

Hydrocodone (Lortab, Norco, Vicodin)

Hydromorphone (Dilaudid, Exalgo)

Hydromorphone-3-beta-glucuronide (hydromorphone metabolite)

Hydroxy-Ethyl Flurazepam (Metabolite of Flurazepam) (Dalmane)

Killer Weed (Phencyclidine)

Librium (Chlordiazepoxide)

Lomaira (Phentermine)

Lorazepam (Ativan)

Luminal (Phenobarbital)

Marijuana (Tetrahydrocannabinol)

MDA (Methylenedioxyamphetamine) Metabolite for Methylenedioxyethylamphetamine (MDEA) and Methylenedioxymethamphetamine (MDMA)

MDMA (Methylenedioxymethamphetamine)

Mebaral (Mephobarbital)

Meperidine (Demerol)

Mephobarbital (Mebaral)

Methadone (Dolophine)

Methadone metabolite (EDDP)

Methamphetamines (Desoxyn)

Methylenedioxyamphetamine (MDA) Metabolite for Methylenedioxyethylamphetamine (MDEA) and Methylenedioxymethamphetamine (MDMA)

Methylenedioxymethamphetamine (MDMA)

Morphine (Avinza, Kadian, MS Contin)

Morphine-6-beta-glucuronide (morphine metabolite

N-desmethyltapentadol (Tapentadol metabolite)

Naloxone (Narcan)

Naloxone-3-beta-glucuronide (Naloxone metabolite)

Nembutal (Pentobarbital)

Norbuprenorphine (Buprenorphine metabolite)

Norbuprenorphine glucuronide (Buprenorphine metabolite)

Nordiazepam (Tranxene)

Norfentanyl (fentanyl metabolite)

Norhydrocodone (hydrocodone metabolite)

Normeperidine (Meperidine metabolite)

Noroxycodone (oxycodone metabolite)

Noroxymorphone (Oxymorphone metabolite)

Norpropoxyphene (propoxyphene metabolite)

O-desmethyltramadol (Tramadol metabolite)

Opiates

Opioid

Oxazepam (Serax)

Oxycodone (Endocet, Percocet, Oxycontin)

Oxymorphone (Numorphan, Opana)

Oxymorphone-3-beta-glucuronide (Oxymorphone metabolite)

Pain Management

PCP (Phencyclidine)

Pentobarbital (Nembutal)

Pentothal (Thiopental)

Phencyclidine (PCP)

Phenobarbital

Propoxyphene (Darvon, Darvocet)

Qsymia (Phentermine)

Restoril (Temazepam)

Ritalin (Methylphenidate)

Rocket Fuel (Phencyclidine)

Rohypnol (Flunitrazepam)

Secobarbital (Seconal)

Seconal (Secobarbital)

Serax (Oxazepam)

Solfoton (Phenobarbital)

Speed (Amphetamines)

Sudafed (Pseudoephedrine)

Super Weed

Tapendtadol-beta-glucuronide (Tapentadol metabolite)

Tapentadol (Nucynta)

TCP (Phencyclidine)

Temazepam (Restoril)

Tetrahydrocannabinol (THC)

THC (Tetrahydrocannabinol)

Thiopental (Pentothal)

Toxicology Screen, Drugs

Tramadol (Tradol, Ultram, Ultracet)

Tranxene (Clorazepate)

Triazolam (Halcion)

Tuinal (Amobarbital and Secobarbital)

UDS

Valium (Diazepam)

Vicodin (Hydrocodone)

Vyvanse (Amphetamine)

Xanax (Alprazolam)

Testing Algorithm
Delineates situations when tests are added to the initial order. This includes reflex and additional tests.

Testing begins with an adulterant survey. If the sample is found to be adulterated, testing will end, and the remaining tests will be canceled.

 

If the specimen is normal or only diluted, remaining testing will continue.

 

If immunoassay screen is positive, confirmation testing can be ordered separately. Confirmation with quantification of positives for barbiturates, cocaine and metabolites, tetrahydrocannabinol metabolite, and ethyl glucuronide/ethyl sulfate will be performed at an additional charge.

Specimen Type
Describes the specimen type validated for testing

Urine

Ordering Guidance

This test does not screen for drug classes other than those listed above.

Specimen Required
Defines the optimal specimen required to perform the test and the preferred volume to complete testing

Supplies: Urine Container, 60 mL (T313)

Collection Container/Tube: Plastic urine container

Submission Container/Tube: Plastic, 60 mL urine container

Specimen Volume: 30 mL

Collection Instructions:

1. Collect a random urine specimen.

2. Submit 30 mL in 1 plastic bottle.

3. No preservative.

Additional Information:

1. No specimen substitutions.

2. Submitting less than 30 mL may compromise the ability to perform all necessary testing.

3. STAT requests are not accepted for this procedure.

Specimen Minimum Volume
Defines the amount of sample necessary to provide a clinically relevant result as determined by the Testing Laboratory

20 mL

Reject Due To
Identifies specimen types and conditions that may cause the specimen to be rejected

  All specimens will be evaluated at Mayo Clinic Laboratories for test suitability.

Specimen Stability Information
Provides a description of the temperatures required to transport a specimen to the performing laboratory, alternate acceptable temperatures are also included

Specimen Type Temperature Time Special Container
Urine Refrigerated (preferred) 14 days
Frozen 14 days

Useful For
Suggests clinical disorders or settings where the test may be helpful

Detecting drug use involving stimulants, barbiturate, benzodiazepines, cocaine, opioids, tetrahydrocannabinol, and alcohol

 

This test is not intended for use in employment-related testing.

Testing Algorithm
Delineates situations when tests are added to the initial order. This includes reflex and additional tests.

Testing begins with an adulterant survey. If the sample is found to be adulterated, testing will end, and the remaining tests will be canceled.

 

If the specimen is normal or only diluted, remaining testing will continue.

 

If immunoassay screen is positive, confirmation testing can be ordered separately. Confirmation with quantification of positives for barbiturates, cocaine and metabolites, tetrahydrocannabinol metabolite, and ethyl glucuronide/ethyl sulfate will be performed at an additional charge.

Clinical Information
Discusses physiology, pathophysiology, and general clinical aspects, as they relate to a laboratory test

This test uses screening techniques that involves immunologic testing and high-resolution accurate mass spectrometry screening for drugs by class. All positive immunoassay screening results are confirmed by gas chromatography-mass spectrometry (GC-MS) or liquid chromatography-tandem mass spectrometry (LC-MS/MS), and quantitated, before a positive result is reported.

 

The following drugs/drug classes are tested by immunoassay and confirmed by GC-MS:

-Barbiturates

-Cocaine

-Tetrahydrocannabinol

 

Ethyl glucuronide is also screened using an immunoassay and confirmation of ethyl glucuronide/ethyl sulfate is performed using LC-MS/MS.

 

The targeted opioid, benzodiazepine, and stimulant screen portions are performed using liquid chromatography-tandem mass spectrometry, high-resolution accurate mass (HRAM) and are completed for all opioids, benzodiazepines, and stimulants. Opioids are a large class of medications commonly used to relieve acute and chronic pain or help manage opioid abuse and dependence. Medications that fall into this class include buprenorphine, codeine, fentanyl, hydrocodone, hydromorphone, methadone, morphine, oxycodone, oxymorphone, tapentadol, tramadol, and others. Opioids work by binding to the opioid receptors that are found in the brain, spinal cord, gastrointestinal tract, and other organs. Common side effects include drowsiness, confusion, nausea, constipation, and, in severe cases, respiratory depression depending on the dose. These medications can also produce physical and psychological dependence and have a high risk for abuse and diversion, which is one of the main reasons many professional practice guidelines recommend compliance testing in patients prescribed these medications.

 

Opioids are readily absorbed from the gastrointestinal tract, nasal mucosa, lungs, and after subcutaneous or intermuscular injection. Opioids are primarily excreted from the kidney in both free and conjugated forms. This assay doesn't hydrolyze the urine sample and looks for both parent drugs and metabolites (including glucuronide forms). The detection window for most opioids in urine is approximately 1 to 3 days with longer detection times for some compounds (ie, methadone).

 

Benzodiazepines represent a large family of medications used to treat a wide range of disorders from anxiety to seizures and are also used in pain management. With a high risk for abuse and diversion, professional practice guidelines recommend compliance monitoring for these medications using urine drug tests. However, traditional benzodiazepine immunoassays suffer from a lack of cross-reactivity with all the benzodiazepines, so many compliant patients taking clonazepam (Klonopin) or lorazepam (Ativan) may screen negative by immunoassay but are positive when confirmatory testing is done. The new targeted benzodiazepine screening test provides a more sensitive and specific test to check for compliance to all the commonly prescribed benzodiazepines and looks for both parent and metabolites in the urine.

 

Stimulants are sympathomimetic amines that stimulate the central nervous system activity and, in part, suppress the appetite. Amphetamine and methamphetamine are also prescription drugs used in the treatment of narcolepsy and attention-deficit disorder/attention-deficit hyperactivity disorder (ADHD). Methylphenidate is another stimulant used to treat ADHD. Phentermine is indicated for the management of obesity. All of the other amphetamines (eg, methylenedioxymethamphetamine: MDMA) are Drug Enforcement Administration scheduled Class I compounds. Due to their stimulant effects, the drugs are commonly sold illicitly and abused. Physiological symptoms associated with very high amounts of ingested amphetamine or methamphetamine include elevated blood pressure, dilated pupils, hyperthermia, convulsions, and acute amphetamine psychosis.

 

Ethyl glucuronide is a direct metabolite of ethanol that is formed by enzymatic conjugation of ethanol with glucuronic acid. Alcohol in urine is normally detected for only a few hours, whereas ethyl glucuronide can be detected in the urine for 1 to 5 days. This procedure uses immunoassay reagents that are designed to produce a negative result when no drugs are present in a natural (eg, unadulterated) specimen of urine; the assay is designed to have a high true-negative rate. Like all immunoassays, it can have a false-positive rate due to cross-reactivity with natural chemicals and drugs other than those they were designed to detect. The immunoassay also has a false-negative rate to the antibody's ability to cross-react with different drugs in the class being screened for.

 

This test is intended to be used in a setting where the test results can be used to make a definitive diagnosis

Reference Values
Describes reference intervals and additional information for interpretation of test results. May include intervals based on age and sex when appropriate. Intervals are Mayo-derived, unless otherwise designated. If an interpretive report is provided, the reference value field will state this.

ADULTERANT SURVEY:

Cutoff concentrations

Oxidants: 200 mg/L

Nitrites: 500 mg/L

 

DRUG IMMUNOASSAY PANEL:

Negative

Screening cutoff concentrations:

Barbiturates: 200 ng/mL

Cocaine (benzoylecgonine-cocaine metabolite): 150 ng/mL

Tetrahydrocannabinol carboxylic acid: 50 ng/mL

This report is intended for use in clinical monitoring or management of patients. It is not intended for use in employment-related testing.

 

TARGETED OPIOID SCREEN:

Not Detected

 

Cutoff concentrations:

Codeine: 25 ng/mL

Codeine-6-beta-glucuronide: 100 ng/mL

Morphine: 25 ng/mL

Morphine-6-beta-glucuronide: 100 ng/mL

6-monoacetylmorphine: 25 ng/mL

Hydrocodone: 25 ng/mL

Norhydrocodone: 25 ng/mL

Dihydrocodeine: 25 ng/mL

Hydromorphone: 25 ng/mL

Hydromorphone-3-beta-glucuronide: 100 ng/mL

Oxycodone: 25 ng/mL

Noroxycodone: 25 ng/mL

Oxymorphone: 25 ng/mL

Oxymorphone-3-beta-glucuronide: 100 ng/mL

Noroxymorphone: 25 ng/mL

Fentanyl: 2 ng/mL

Norfentanyl: 2 ng/mL

Meperidine: 25 ng/mL

Normeperidine: 25 ng/mL

Naloxone: 25 ng/mL

Naloxone-3-beta-glucuronide: 100 ng/mL

Methadone: 25 ng/mL

EDDP: 25 ng/mL

Propoxyphene: 25 ng/mL

Norpropoxyphene: 25 ng/mL

Tramadol: 25 ng/mL

O-desmethyltramadol: 25 ng/mL

Tapentadol: 25 ng/mL

N-desmethyltapentadol: 50 ng/mL

Tapentadol-beta-glucuronide: 100 ng/mL

Buprenorphine: 5 ng/mL

Norbuprenorphine: 5 ng/mL

Norbuprenorphine glucuronide: 20 ng/mL

 

TARGETED BENZODIAZEPINE SCREEN:

Not Detected

 

Cutoff concentrations:

Alprazolam: 10 ng/mL

Alpha-Hydroxyalprazolam: 10 ng/mL

Alpha-Hydroxyalprazolam Glucuronide: 50 ng/mL

Chlordiazepoxide: 10 ng/mL

Clobazam: 10 ng/mL

N-Desmethylclobazam: 200 ng/mL

Clonazepam: 10 ng/mL

7-aminoclonazepam: 10 ng/mL

Diazepam: 10 ng/mL

Nordiazepam: 10 ng/mL

Flunitrazepam: 10 ng/mL

7-aminoflunitrazepam: 10 ng/mL

Flurazepam: 10 ng/mL

2-Hydroxy Ethyl Flurazepam: 10 ng/mL

Lorazepam: 10 ng/mL

Lorazepam Glucuronide: 50 ng/mL

Midazolam: 10 ng/mL

Alpha-Hydroxy Midazolam: 10 ng/mL

Oxazepam: 10 ng/mL

Oxazepam Glucuronide: 50 ng/mL

Prazepam: 10 ng/mL

Temazepam: 10 ng/mL

Temazepam Glucuronide: 50 ng/mL

Triazolam: 10 ng/mL

Alpha-Hydroxy Triazolam: 10 ng/mL

Zolpidem: 10 ng/mL

Zolpidem Phenyl-4-Carboxylic acid: 10 ng/mL

 

TARGETED STIMULANT SCREEN:

Not Detected

 

Cutoff concentrations:

Methamphetamine: 100 ng/mL

Amphetamine: 100 ng/mL

3,4-methylenedioxymethamphetamine (MDMA): 100 ng/mL

3,4-methylenedioxy-N-ethylamphetamine (MDEA): 100 ng/mL

3,4-methylenedioxyamphetamine (MDA): 100 ng/mL

Ephedrine: 100 ng/mL

Pseudoephedrine: 100 ng/mL

Phentermine: 100 ng/mL

Phencyclidine (PCP): 20 ng/mL

Methylphenidate: 20 ng/mL

Ritalinic acid: 100 ng/mL

 

ETHYL GLUCURONIDE SCREEN:

Negative

 

Screening cutoff concentrations:

Ethyl Glucuronide: 500 ng/mL

Interpretation
Provides information to assist in interpretation of the test results

A positive result derived by this testing indicates that the patient has used one of the drugs detected by these techniques in the recent past. See individual tests (eg, COKEU / Cocaine and Metabolite Confirmation, Random, Urine) for more information.

 

For information about drug testing, including estimated detection times, see Specific Drug Groups.

Cautions
Discusses conditions that may cause diagnostic confusion, including improper specimen collection and handling, inappropriate test selection, and interfering substances

In regards to ethyl glucuronide testing, care should be taken when interpreting results since there are many factors (eg, fluid intake and other biologic factors) that may influence a urine test result. It is possible that substances other than those investigated in the specificity study may interfere with the test and cause false-positive or false-negative results.

Clinical Reference
Recommendations for in-depth reading of a clinical nature

1. Physicians' Desk Reference; 60th ed. Medical Economics Company, 2006

2. Bruntman LL, ed. Goodman and Gilman's: The Pharmacological Basis of Therapeutics. 11th ed. McGraw-Hill Book Company; 2006

3. Langman LJ, Bechtel L, Meier BM, Holstege CP: Clinical toxicology In: Rifai N, Horwath AR, Wittwer CT, eds: Tietz Textbook of Clinical Chemistry and Molecular Diagnostics. 6th ed. Elsevier; 2018:832-887

4. Gutstein HB, Akil H: Opioid analgesics. In: Brunton LL, Lazo JS, Parker KL, eds: Goodman and Gilman's: The Pharmacological Basis of Therapeutics. 11th ed. McGraw-Hill Companies; 2006

5. Chronic Pain in America: Roadblocks to Relief, survey conducted for the American Pain Society, The American Academy of the Pain Medicine and Janssen Pharmaceutical, 1999

6. Magnani B, Kwong T: Urine drug testing for pain management. Clin Lab Med. 2012;32(32):379-390

7. Jannetto PJ, Bratanow NC, Clark WA, et al: Executive summary: American Association of Clinical Chemistry Laboratory Medicine Practice Guideline-using clinical laboratory tests to monitor drug therapy in pain management patients. J Appl Lab Med. 2018;2(4):489-526

8. McMillin GA, Marin SJ, Johnson-Davis KL, Lawlor BG, Strathmann FG: A hybrid approach to urine drug testing using high-resolution mass spectrometry and select immunoassays. Am J Clin Pathol. 2015;143(2):234-240

9. Cone EJ, Caplan YH, Black DL, Robert T, Moser F: Urine drug testing of chronic pain patients: licit and illicit drug patterns. J Anal Toxicol. 2008;32(8):530-543

Method Description
Describes how the test is performed and provides a method-specific reference

Adulterant:

All results are measured using spectrophotometry at wavelengths specified by the reagent manufacturer. The use of a refractometer may also be used in the specific gravity measurement.(Package insert: Creatinine plus ver 2, Specimen Validity Test Nitrite, Specimen Validity Test Oxidant, Specimen Validity Test pH, Specimen Validity Test Specific Gravity, Roche Diagnostics; 12/2016)

 

Drug Panel:

The barbiturate, cocaine metabolite, and tetrahydrocannabinol metabolite assays are based on the kinetic interaction of microparticles in a solution as measured by changes in light transmission. In the absence of sample drug, soluble drug conjugates bind to antibody-bound microparticles, causing the formation of particle aggregates. As the aggregation reaction proceeds in the absence of sample drug, the absorbance increases. When a urine sample contains the drug in question, this drug competes with the drug derivative conjugate for microparticle-bound antibody. Antibody bound to sample drug is no longer available to promote particle aggregation, and subsequent particle lattice formation is inhibited. The presence of sample drug diminishes the increasing absorbance in proportion to the concentration of drug in the sample. Sample drug content is determined relative to the value obtained for a known cutoff concentration of drug.(Package inserts: Barbiturates. Roche Diagnostics; 11/2017; Cannabinoids. Roche Diagnostics; 11/2017; Cocaine. Roche Diagnostics; 11/2017)

 

Targeted Screening Panels for opioids, benzodiazepines, and stimulants:

The urine sample is diluted with internal standard and clinical laboratory reagent water and then analyzed by liquid chromatography- tandem mass spectrometry using a high resolution-accurate mass orbi-trap detector.(Unpublished Mayo method)

 

Ethyl Glucuronide Screen:

This assay is a homogeneous enzyme-linked immunosorbent assay (EIA) technique. The assay will be performed semiquantitatively. The assay is based on competition between free drug in the urine sample, and a drug labeled with the enzyme glucose-6-phosphate dehydrogenase for a fixed amount of specific antibody binding sites. Active enzyme converts nicotinamide adenine dinucleotide (NAD+) to NADH, which results in an absorbance change that can be measured spectrophotometrically at 340 nm.(Package insert: DRI Ethyl Glucuronide Assay. Microgenics Corporation; 09/2015)

PDF Report
Indicates whether the report includes an additional document with charts, images or other enriched information

No

Day(s) Performed
Outlines the days the test is performed. This field reflects the day that the sample must be in the testing laboratory to begin the testing process and includes any specimen preparation and processing time before the test is performed. Some tests are listed as continuously performed, which means that assays are performed multiple times during the day.

Monday through Friday

Report Available
The interval of time (receipt of sample at Mayo Clinic Laboratories to results available) taking into account standard setup days and weekends. The first day is the time that it typically takes for a result to be available. The last day is the time it might take, accounting for any necessary repeated testing.

2 to 5 days

Specimen Retention Time
Outlines the length of time after testing that a specimen is kept in the laboratory before it is discarded

14 days

Performing Laboratory Location
Indicates the location of the laboratory that performs the test

Rochester

Fees
Several factors determine the fee charged to perform a test. Contact your U.S. or International Regional Manager for information about establishing a fee schedule or to learn more about resources to optimize test selection.

  • Authorized users can sign in to Test Prices for detailed fee information.
  • Clients without access to Test Prices can contact Customer Service 24 hours a day, seven days a week.
  • Prospective clients should contact their Regional Manager. For assistance, contact Customer Service.

Test Classification
Provides information regarding the medical device classification for laboratory test kits and reagents. Tests may be classified as cleared or approved by the US Food and Drug Administration (FDA) and used per manufacturer instructions, or as products that do not undergo full FDA review and approval, and are then labeled as an Analyte Specific Reagent (ASR) product.

This test was developed, and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the US Food and Drug Administration.

CPT Code Information
Provides guidance in determining the appropriate Current Procedural Terminology (CPT) code(s) information for each test or profile. The listed CPT codes reflect Mayo Clinic Laboratories interpretation of CPT coding requirements. It is the responsibility of each laboratory to determine correct CPT codes to use for billing.

CPT codes are provided by the performing laboratory.

80307

80347

80364

80326

G0482 (if appropriate)

LOINC® Information

Test Id Test Order Name Order LOINC Value
CSMEU CSM Enhanced Profile,21, HRMS/IA, U In Process
Result Id Test Result Name Result LOINC Value
Result LOINC Value Tooltip

Test Setup Resources

Setup Files
Test setup information contains test file definition details to support order and result interfacing between Mayo Clinic Laboratories and your Laboratory Information System.

Excel | Pdf

Sample Reports
Normal and Abnormal sample reports are provided as references for report appearance.

Normal Reports | Abnormal Reports

SI Sample Reports
International System (SI) of Unit reports are provided for a limited number of tests. These reports are intended for international account use and are only available through MayoLINK accounts that have been defined to receive them.

SI Normal Reports | SI Abnormal Reports